Regulatory Compliance

Louisville, Colo. – October 08, 2026 -- Ninety-two percent of organizations reported at least one AI-related incident or exposure in the past 12 months, according to a new JumpCloud study of 250 IT leaders in the U.S. and U.K. titled "Enterprise AI Access Is Outpacing Control." More than half of organizations now deploy AI agents capable of changing systems, permissions, or files, yet 59% of those using such agents do not apply the same governance rules used for human employees.

Identity integration lags as AI agents gain system access

Only 41% of organizations using AI agents have fully folded those agents into the identity and access management (IAM) policies governing human users, the study found. The remaining 59% operate without full integration, leaving a structural gap between how human and machine identities are controlled.

Delray Beach, Fla. – – October 08, 2026 -- The global Active Pharmaceutical Ingredients (API) market will grow from USD 149.02 billion in 2026 to USD 199.42 billion by 2031, a 6.0% compound annual growth rate, according to new data from MarketsandMarkets.

North America commands 43.1% of global API sales as domestic manufacturing investment accelerates

North America held the largest regional share of the API market in 2025 at 43.1%, driven by established pharmaceutical R&D infrastructure and rising investment in domestic production capacity. The US leads regional output in high-value and complex API development, supported by a dense base of pharmaceutical companies, contract manufacturing organizations, and specialized API producers.

Sarasota – October 08, 2026 -- 360 Orthopedics has become one of the first orthopedic practices in Florida to receive the Center of Excellence (COE) designation for workers' compensation care, a credential tied to measurable standards in access, documentation and return-to-work coordination.

Designation targets delays that drive up claim costs for employers and carriers

The COE evaluation assesses five operational areas: timely orthopedic evaluation and treatment, accurate medical documentation, communication among patients, employers, adjusters and nurse case managers, coordination of authorizations and follow-up care, and structured return-to-work planning. For employers and insurers, process delays in any of these areas can extend time away from work and increase claim complexity and cost.

Las Vegas – October 08, 2026 -- Frax has become the first crypto company to have an ICANN top-level domain application revealed, with .frax published under the 2026 New Generic Top-Level Domains Program. If delegated, .frax would function as a globally recognized internet domain alongside .com and .org.

.frax Would Link Blockchain-Based Naming With the Global DNS

Frax intends .frax to be the first end-to-end top-level domain connecting the traditional internet with onchain infrastructure. Users would register and manage .frax domains through Frax Name Service (FNS) on Frax's blockchain network, Fraxtal, while those domains continue to resolve through the standard global Domain Name System.

Wilmington, Del. – October 08, 2026 -- Progressive has claimed first place overall and for mobile web in Keynova Group's Q3 2026 Mobile Insurance Scorecard, while Allstate took the top spot for mobile app experience, according to the semi-annual benchmark of the 12 largest U.S. auto and property insurers.

Carriers push personalized savings tools as premiums climb

One-third of the 12 carriers evaluated have introduced enhanced mobile tools that let existing policyholders identify and apply for new discounts, policy options or deductible changes, moving beyond discount offers limited to new-policy quoting. These guided savings assessments factor in a policyholder's current deductibles, coverages and discounts to generate targeted recommendations.

New York – – October 08, 2026 -- The U.S. Department of Veterans Affairs has integrated CLEAR's secure identity platform, CLEAR1, into a pilot program designed to simplify account access for the nation's roughly 17 million living Veterans while combating fraud across federal benefit programs.

VA.gov sign-in now offers biometric verification via selfie

Veterans can now create or access their VA.gov account using CLEAR1, which combines biometrics, government-issued identification and trusted data sources to verify identity. After a one-time setup, future sign-ins require only a selfie, reducing reliance on traditional usernames and passwords. VA operates the largest integrated health care system in the country, serving 9.1 million enrolled Veterans annually, and VA.gov serves as the primary digital gateway to earned benefits and services.

New York – October 08, 2026 -- Elsevier has signed a strategic content agreement with the JAMA Network to integrate full-text content and visuals from 13 JAMA journals into ClinicalKey AI, its clinical-grade AI workspace, giving clinicians access to more than half of the world's top 100 medical journals through the platform.

Agreement covers 13 JAMA Network titles including flagship journal and specialty publications

The deal brings all published full-text content and visuals from JAMA, JAMA Network Open, and 11 specialty journals -- JAMA Cardiology, JAMA Dermatology, JAMA Health Forum, JAMA Internal Medicine, JAMA Neurology, JAMA Oncology, JAMA Ophthalmology, JAMA Otolaryngology-Head & Neck Surgery, JAMA Pediatrics, JAMA Psychiatry and JAMA Surgery -- into the responses clinicians receive through ClinicalKey AI. Content is available to ClinicalKey AI customers immediately.

Orange County, Calif. – October 08, 2026 -- The Institute for Molecular Medicine (IMM) and Nuravax have dosed the first four participants in TAURUS-1980, a Phase 1 trial testing AV-1980R, described as the world's first active immunotherapy targeting pathological tau protein linked to Alzheimer's disease.

Trial targets at-risk adults before cognitive symptoms appear

TAURUS-1980 will enroll up to 48 cognitively unimpaired adults aged 65 to 80 who have biomarker-confirmed brain amyloid pathology, a known precursor to Alzheimer's. Participants are randomized 3:1 to receive AV-1980R or placebo across three ascending-dose cohorts of 20, 60, and 180 micrograms.

Sarasota, Fla. – October 08, 2026 -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) reported that its Bisphosphocin compound Nu-8, delivered intravesically to rodents infected with E. coli, achieved up to 97% inhibition of bacterial growth using a 10% solution, against no effect in a vehicle control group.

Nu-8 targets drug-resistant bacteria linked to catheter-associated UTIs

The Bisphosphocin class has shown in vitro activity against a broad range of resistant bacteria common in urinary tract infections, including E. coli, K. pneumoniae, and P. aeruginosa, and against biofilm-forming organisms. Complicated UTIs, particularly catheter-associated urinary tract infections, are frequently driven by drug-resistant strains and biofilm formation, a persistent challenge for hospital infection control.

Mesa, Ariz. – October 08, 2026 -- Bright Path, a U.S. pharmaceutical manufacturer, has been named a 2026 AZBio Fast Lane Award honoree by the Arizona Bioindustry Association, recognizing milestones reached over the past 18 months including a first-of-its-kind FDA manufacturing designation and committed commercial production of hospital medicines facing chronic shortages. The company was honored at the 23rd Annual AZBio Awards at the Phoenix Convention Center during Arizona Bioscience Week.